ClinicalTrials.gg
CompletedNCT02536339Updated Dec 7, 2021Results posted

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

A Phase 2 interventional study of Pertuzumab and Trastuzumab in Metastatic Breast Cancer, sponsored by Genentech, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-07.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
84th of 104
40 · median 100
Started
2015
with 7 others
Phase 2
59 of 104
17 open now
Registered
38th of 104
by date
Lead sponsor
2 of 104
Genentech, Inc.

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 84th largest by enrollment, is one of 8 that started in 2015, is one of 59 in phase 2, and was the 38th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed -positive MBC
  • Progression of or new after completion of whole-brain radiotherapy or stereotactic radiosurgery
  • Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment
  • Stable systemic disease
  • (ECOG) performance status of 0 or 1
  • at least 50%
  • Adequate hematologic, renal, and hepatic function
  • more than 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Progression of systemic disease at Screening
  • History of intolerance or to study drug
  • Use of certain therapies within 21 days prior to enrollment
  • Current anthracycline use
  • Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use
  • Active infection
  • Pregnant or lactating women
  • Significant history or risk of cardiac disease
  • Symptomatic intrinsic lung disease or lung involvement
  • History of other within the last 5 years
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab

    Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

    Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

    Also known as: Perjeta, RO4368451

  • Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

    Also known as: Herceptin, RO0452317

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. A CR was defined as the disappearance of all CNS target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically; for non-target lesions, a CR was the disappearance of all enhancing CNS non-target lesions and no new CNS lesions. A PR was defined as at least a 30% decrease in the sum longest diameter (LD) of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; and stable or improved clinically. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

    Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 3.5 years)

Secondary outcomes

  1. Median Duration of Response in the CNS, Assessed Using RANO-BM Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. Among participants who achieved an objective response, duration of response in the CNS was defined as the time from documentation of the first CR or PR to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of response was censored on the last date the participant was known to be progression free. Duration of response was estimated by the Kaplan-Meier method.

    Time frame: From documentation of first complete response (CR) or partial response (PR) to the time of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 3.5 years)

  2. Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or Stable Disease [SD] ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

    Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)

  3. Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥4 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.

    Time frame: From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥4 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)

  4. Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

    Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)

  5. Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria

    Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥6 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.

    Time frame: From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥6 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)

  6. Progression-Free Survival (CNS), Assessed Using RANO-BM Criteria

    Progression-free survival (CNS) was defined as the time from the date of first dose to disease progression in the CNS or death from any cause. If no progressive disease in the CNS and no death occurred, progression-free survival (CNS) was censored on the date of the last CNS tumor assessment. If a post-baseline assessment was not available, progression-free survival (CNS) was censored on Day 1.

    Time frame: From the date of first dose to disease progression in the CNS or death from any cause, whichever occurred first (up to approximately 5 years)

  7. Progression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Progression-free survival (systemic) was defined as the time from the date of first dose to systemic disease progression or death from any cause. If no systemic disease progression and no death occurred, progression-free survival (systemic) was censored on the date of the last systemic tumor assessment. If a post-baseline assessment was not available, progression-free survival (systemic) was censored on Day 1.

    Time frame: From the date of first dose to systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)

  8. Progression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.1

    Progression-free survival (CNS or systemic) was defined as the time from the date of first dose to CNS or systemic disease progression or death from any cause. If no CNS or systemic disease progression and no death occurred, data was censored on the date of the last CNS or systemic tumor assessment, whichever occurred first. If a post-baseline assessment was not available, data was censored on Day 1.

    Time frame: From the date of first dose to CNS or systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)

  9. Overall Survival

    Overall survival was defined as the period from the date of first dose until the date of death from any cause. If no death occurred, overall survival was censored on the last date the participant was known to be alive.

    Time frame: From the date of first dose until death due to any cause (up to approximately 5 years)

  10. Number of Deaths by Time (≤30 or >30 Days) From Last Study Drug Administration and by Primary Cause of Death

    Time frame: From date of first dose until death due to any cause (up to approximately 5 years)

  11. Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) by Highest Grade of Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

    Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  12. Number of Participants With at Least One Treatment-Emergent Serious Adverse Event (SAE) by Highest Grade of Severity, According to NCI-CTCAE v4.0

    Treatment-emergent serious adverse events (SAEs) were defined as all adverse events that met seriousness criteria (as defined in the protocol; same as the ClinicalTrials.gov definition) occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All SAEs were graded for severity using the NCI-CTCAE v4.0; any SAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated; and Grade 5 = death related to adverse event. The terms "severe" and "serious" are not synonymous and are independently assessed for each adverse event. Multiple occurrences of SAEs were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  13. Number of Participants With at Least One TEAE Leading to Withdrawal of Any Study Drug, Pertuzumab Only, or Both Pertuzumab and Trastuzumab, by Highest Grade of Severity According to NCI-CTCAE v4.0

    Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  14. Number of Participants With at Least One TEAE Leading to Pertuzumab Infusion Delay, Slow Down, or Interruption, by Highest Grade of Severity According to NCI-CTCAE v4.0

    Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  15. Number of Participants With at Least One TEAE Leading to Trastuzumab Dose Modification by Highest Grade of Severity According to NCI-CTCAE v4.0

    Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  16. Percentage of Participants With at Least One TEAE of Special Interest by Highest Grade of Severity, According to NCI-CTCAE v4.0

    Protocol-defined TEAEs of special interest, occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment, included the following: An elevated ALT or AST (\>3 times baseline value) in combination with either an elevated total bilirubin (\>2 times the upper limit of normal) or clinical jaundice; Suspected transmission of an infectious agent by the study treatment; Congestive heart failure; An asymptomatic decline in LVEF (a value 10 percentage points below baseline or lower, and \<45%) that requires treatment or that leads to discontinuation of study treatment. All TEAEs of special interest were graded for severity using the NCI-CTCAE v4.0. Multiple occurrences of TEAEs of special interest were counted only once per participant at the highest (worst) grade.

    Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)

  17. Median Left Ventricular Ejection Fraction (LVEF) Values Over Time

    Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least 50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study.

    Time frame: Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)

  18. Number of Participants by Investigator Interpretation of Left Ventricular Ejection Fraction (LVEF) Assessments Over Time

    Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least (≥)50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF \>45% or LVEF 40-45% with less than (\<)10% points drop below baseline; 'Abnormal' was defined as LVEF \<40% or LVEF ≥10% points drop below baseline, and clinically significant versus non-clinically significant was subject to the investigator's assessment of whether symptoms were present or absent.

    Time frame: Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)

  19. Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Hematology Tests Over Time

    Clinical laboratory tests for hematology parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.

    Time frame: Baseline, Weeks 18, 36, and 60 (up to approximately 5 years)

  20. Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Blood Chemistry Tests Over Time

    Clinical laboratory tests for blood chemistry parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.

    Time frame: Weeks 6, 12, and 18, and Unscheduled Visits (up to approximately 5 years)

  21. Observed Trough Serum Concentrations (Cmin) of Pertuzumab at Specified Timepoints

    Per protocol eligibility criteria, participants were not required to be pertuzumab naïve; therefore pertuzumab was detectable in some participants pre-dose at Week 1.

    Time frame: Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16

  22. Maximum Serum Concentrations (Cmax) of Pertuzumab at Specified Timepoints

    Time frame: Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16

  23. Observed Trough Serum Concentrations (Cmin) of Trastuzumab at Specified Timepoints

    Per protocol eligibility criteria, participants were not required to be trastuzumab naïve; therefore trastuzumab was detectable in some participants pre-dose at Week 1.

    Time frame: Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16

  24. Maximum Serum Concentrations (Cmax) of Trastuzumab at Specified Timepoints

    Time frame: Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16

  25. Symptom Severity Scale Score Over Time, Assessed by Participant Reporting on the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Questionnaire

    The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms (Cleeland et al. 2000) that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom severity scale, participants rate the severity of their symptoms in the last 24 hours on 0-10 numeric scales, ranging from 0 = "not present" to 10 = "as bad as you can imagine." The MDASI-BT symptom severity scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 12 of the 22 severity scale items. The score will be considered missing if less than 12 items are completed.

    Time frame: Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64

  26. Symptom Interference Scale Score Over Time, Assessed by Participant Reporting on the MDASI-BT Questionnaire

    The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom interference scale, participants rate interference with daily activities caused by their symptoms on 0-10 numeric scales ranging from 0 = "did not interfere" to 10 = "interfered completely." The MDASI-BT symptom interference scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 4 of the 6 interference scale items. The score will be considered missing if less than 4 items are completed.

    Time frame: Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64

07

Results

Posted Mar 27, 2020

Participant flow

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab
Started40
Received at least one dose of study drug39
Efficacy-evaluable population37
Completed12
Not completed28
Withdrew: Death20
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up2
Withdrew: Treatment discontinued2
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. A CR was defined as the disappearance of all CNS target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically; for non-target lesions, a CR was the disappearance of all enhancing CNS non-target lesions and no new CNS lesions. A PR was defined as at least a 30% decrease in the sum longest diameter (LD) of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; and stable or improved clinically. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

Time frame:
From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 3.5 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria
Percentage of ParticipantsPertuzumab + Trastuzumab
With Objective Response (Confirmed CR or PR)10.8 (3.03 to 25.42)
Confirmed Complete Response (CR)0.0 (0.00 to 9.49)
Confirmed Partial Response (PR)10.8 (3.03 to 25.42)
Without Objective Response89.2 (NA to NA)
SecondaryMedian Duration of Response in the CNS, Assessed Using RANO-BM Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. Among participants who achieved an objective response, duration of response in the CNS was defined as the time from documentation of the first CR or PR to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of response was censored on the last date the participant was known to be progression free. Duration of response was estimated by the Kaplan-Meier method.

Time frame:
From documentation of first complete response (CR) or partial response (PR) to the time of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 3.5 years)
Reported as:
Median · Months
Median Duration of Response in the CNS, Assessed Using RANO-BM Criteria
MonthsPertuzumab + Trastuzumab
Median Duration of Response in the CNS, Assessed Using RANO-BM Criteria4.60 (3.19 to 5.59)
SecondaryPercentage of Participants With Clinical Benefit (Confirmed CR, PR, or Stable Disease [SD] ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

Time frame:
From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or Stable Disease [SD] ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria
Percentage of ParticipantsPertuzumab + Trastuzumab
With Clinical Benefit (Confirmed CR,PR,or SD≥4mos)67.6 (50.21 to 81.99)
Confirmed Complete Response (CR)0.0 (0.00 to 9.49)
Confirmed Partial Response (PR)10.8 (3.03 to 25.42)
Confirmed Stable Disease (SD) ≥4 Months56.8 (39.49 to 72.90)
Without Clinical Benefit32.4 (NA to NA)
SecondaryMedian Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥4 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.

Time frame:
From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥4 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)
Reported as:
Median · Months
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria
MonthsPertuzumab + Trastuzumab
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria6.64 (3.2 to 56.1)
SecondaryPercentage of Participants With Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.

Time frame:
From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria
Percentage of ParticipantsPertuzumab + Trastuzumab
With Clinical Benefit (Confirmed CR,PR,or SD≥6mos)51.4 (34.40 to 68.08)
Confirmed Complete Response (CR)0.0 (0.00 to 9.49)
Confirmed Partial Response (PR)10.8 (3.03 to 25.42)
Confirmed Stable Disease (SD) ≥6 Months40.5 (24.75 to 57.90)
Without Clinical Benefit48.6 (NA to NA)
SecondaryMedian Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria

Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥6 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.

Time frame:
From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥6 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)
Reported as:
Median · Months
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria
MonthsPertuzumab + Trastuzumab
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria9.23 (3.2 to 56.1)
SecondaryProgression-Free Survival (CNS), Assessed Using RANO-BM Criteria

Progression-free survival (CNS) was defined as the time from the date of first dose to disease progression in the CNS or death from any cause. If no progressive disease in the CNS and no death occurred, progression-free survival (CNS) was censored on the date of the last CNS tumor assessment. If a post-baseline assessment was not available, progression-free survival (CNS) was censored on Day 1.

Time frame:
From the date of first dose to disease progression in the CNS or death from any cause, whichever occurred first (up to approximately 5 years)
Reported as:
Median · Months
Progression-Free Survival (CNS), Assessed Using RANO-BM Criteria
MonthsPertuzumab + Trastuzumab
Progression-Free Survival (CNS), Assessed Using RANO-BM Criteria4.63 (0.82 to 56.11)
SecondaryProgression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Progression-free survival (systemic) was defined as the time from the date of first dose to systemic disease progression or death from any cause. If no systemic disease progression and no death occurred, progression-free survival (systemic) was censored on the date of the last systemic tumor assessment. If a post-baseline assessment was not available, progression-free survival (systemic) was censored on Day 1.

Time frame:
From the date of first dose to systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)
Reported as:
Median · Months
Progression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
MonthsPertuzumab + Trastuzumab
Progression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)16.26 (0.03 to 55.20)
SecondaryProgression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.1

Progression-free survival (CNS or systemic) was defined as the time from the date of first dose to CNS or systemic disease progression or death from any cause. If no CNS or systemic disease progression and no death occurred, data was censored on the date of the last CNS or systemic tumor assessment, whichever occurred first. If a post-baseline assessment was not available, data was censored on Day 1.

Time frame:
From the date of first dose to CNS or systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)
Reported as:
Median · Months
Progression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.1
MonthsPertuzumab + Trastuzumab
Progression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.14.63 (0.03 to 55.20)
SecondaryOverall Survival

Overall survival was defined as the period from the date of first dose until the date of death from any cause. If no death occurred, overall survival was censored on the last date the participant was known to be alive.

Time frame:
From the date of first dose until death due to any cause (up to approximately 5 years)
Reported as:
Median · Months
Overall Survival
MonthsPertuzumab + Trastuzumab
Overall Survival27.17 (0.82 to 57.49)
SecondaryNumber of Deaths by Time (≤30 or >30 Days) From Last Study Drug Administration and by Primary Cause of Death
Time frame:
From date of first dose until death due to any cause (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Deaths by Time (≤30 or >30 Days) From Last Study Drug Administration and by Primary Cause of Death
ParticipantsPertuzumab + Trastuzumab
All Deaths20
Deaths ≤30 Days From Last Dose of Study Drug1
Deaths >30 Days From Last Dose of Study Drug19
Primary Cause of Death: Progressive Disease16
Primary Cause of Death: Other Cause (and Cancer)1
Primary Cause of Death: Unknown3
SecondaryNumber of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) by Highest Grade of Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) by Highest Grade of Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
ParticipantsPertuzumab + Trastuzumab
Any TEAE - Any Grade38
Any TEAE - Grade 15
Any TEAE - Grade 216
Any TEAE - Grade 314
Any TEAE - Grade 43
Any TEAE - Grade 50
SecondaryNumber of Participants With at Least One Treatment-Emergent Serious Adverse Event (SAE) by Highest Grade of Severity, According to NCI-CTCAE v4.0

Treatment-emergent serious adverse events (SAEs) were defined as all adverse events that met seriousness criteria (as defined in the protocol; same as the ClinicalTrials.gov definition) occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All SAEs were graded for severity using the NCI-CTCAE v4.0; any SAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated; and Grade 5 = death related to adverse event. The terms "severe" and "serious" are not synonymous and are independently assessed for each adverse event. Multiple occurrences of SAEs were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Serious Adverse Event (SAE) by Highest Grade of Severity, According to NCI-CTCAE v4.0
ParticipantsPertuzumab + Trastuzumab
Any SAE - Any Grade7
Any SAE - Grade 10
Any SAE - Grade 21
Any SAE - Grade 35
Any SAE - Grade 42
Any SAE - Grade 50
SecondaryNumber of Participants With at Least One TEAE Leading to Withdrawal of Any Study Drug, Pertuzumab Only, or Both Pertuzumab and Trastuzumab, by Highest Grade of Severity According to NCI-CTCAE v4.0

Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One TEAE Leading to Withdrawal of Any Study Drug, Pertuzumab Only, or Both Pertuzumab and Trastuzumab, by Highest Grade of Severity According to NCI-CTCAE v4.0
ParticipantsPertuzumab + Trastuzumab
Withdrawal of Any Study Drug - Any Grade TEAE2
Withdrawal of Any Study Drug - Grade 3 TEAE2
Withdrawal of Pertuzumab Only - Any Grade TEAE0
Withdrawal of Both Study Drugs - Any Grade TEAE2
Withdrawal of Both Study Drugs - Grade 3 TEAE2
SecondaryNumber of Participants With at Least One TEAE Leading to Pertuzumab Infusion Delay, Slow Down, or Interruption, by Highest Grade of Severity According to NCI-CTCAE v4.0

Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One TEAE Leading to Pertuzumab Infusion Delay, Slow Down, or Interruption, by Highest Grade of Severity According to NCI-CTCAE v4.0
ParticipantsPertuzumab + Trastuzumab
Any TEAE - Any Grade7
Any TEAE - Grade 11
Any TEAE - Grade 24
Any TEAE - Grade 31
Any TEAE - Grade 41
Any TEAE - Grade 50
SecondaryNumber of Participants With at Least One TEAE Leading to Trastuzumab Dose Modification by Highest Grade of Severity According to NCI-CTCAE v4.0

Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One TEAE Leading to Trastuzumab Dose Modification by Highest Grade of Severity According to NCI-CTCAE v4.0
ParticipantsPertuzumab + Trastuzumab
Any TEAE - Any Grade12
Any TEAE - Grade 12
Any TEAE - Grade 24
Any TEAE - Grade 35
Any TEAE - Grade 41
Any TEAE - Grade 50
SecondaryPercentage of Participants With at Least One TEAE of Special Interest by Highest Grade of Severity, According to NCI-CTCAE v4.0

Protocol-defined TEAEs of special interest, occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment, included the following: An elevated ALT or AST (\>3 times baseline value) in combination with either an elevated total bilirubin (\>2 times the upper limit of normal) or clinical jaundice; Suspected transmission of an infectious agent by the study treatment; Congestive heart failure; An asymptomatic decline in LVEF (a value 10 percentage points below baseline or lower, and \<45%) that requires treatment or that leads to discontinuation of study treatment. All TEAEs of special interest were graded for severity using the NCI-CTCAE v4.0. Multiple occurrences of TEAEs of special interest were counted only once per participant at the highest (worst) grade.

Time frame:
From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One TEAE of Special Interest by Highest Grade of Severity, According to NCI-CTCAE v4.0
Percentage of ParticipantsPertuzumab + Trastuzumab
Any TEAE of Special Interest - Any Grade2.6 (0.06 to 13.48)
Asymptomatic Decline in LVEF - Grade 32.6 (0.06 to 13.48)
SecondaryMedian Left Ventricular Ejection Fraction (LVEF) Values Over Time

Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least 50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study.

Time frame:
Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)
Reported as:
Median · Percentage Points of LVEF (%)
Median Left Ventricular Ejection Fraction (LVEF) Values Over Time
Percentage Points of LVEF (%)Pertuzumab + Trastuzumab
Baseline60.00 (50.00 to 75.00)
Week 660.00 (30.00 to 69.00)
Week 1260.00 (51.00 to 73.00)
Week 2460.00 (50.00 to 67.00)
Week 3660.00 (50.00 to 65.00)
Week 4860.00 (48.00 to 64.00)
Week 6062.00 (49.00 to 70.00)
Week 7255.50 (53.00 to 65.00)
Week 8460.00 (55.00 to 62.00)
Week 9663.00 (60.00 to 65.00)
Week 10862.00 (60.00 to 64.00)
Week 12064.00 (64.00 to 64.00)
Week 13264.00 (64.00 to 64.00)
Survival Follow-Up 160.00 (50.00 to 68.00)
Survival Follow-Up 259.00 (53.00 to 75.00)
Survival Follow-Up 360.00 (55.00 to 65.00)
Survival Follow-Up 469.00 (66.00 to 72.00)
Survival Follow-Up 567.00 (60.00 to 72.00)
Survival Follow-Up 657.00 (55.00 to 58.00)
Survival Follow-Up 757.50 (55.00 to 60.00)
Survival Follow-Up 857.00 (55.00 to 59.00)
SecondaryNumber of Participants by Investigator Interpretation of Left Ventricular Ejection Fraction (LVEF) Assessments Over Time

Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least (≥)50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF \>45% or LVEF 40-45% with less than (\<)10% points drop below baseline; 'Abnormal' was defined as LVEF \<40% or LVEF ≥10% points drop below baseline, and clinically significant versus non-clinically significant was subject to the investigator's assessment of whether symptoms were present or absent.

Time frame:
Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants by Investigator Interpretation of Left Ventricular Ejection Fraction (LVEF) Assessments Over Time
ParticipantsPertuzumab + Trastuzumab
Baseline — Normal39
Baseline — Abnormal, Not Clinically Significant0
Baseline — Abnormal, Clinically Significant0
Week 6 — Normal33
Week 6 — Abnormal, Not Clinically Significant0
Week 6 — Abnormal, Clinically Significant1
Week 12 — Normal30
Week 12 — Abnormal, Not Clinically Significant0
Week 12 — Abnormal, Clinically Significant0
Week 24 — Normal14
Week 24 — Abnormal, Not Clinically Significant1
Week 24 — Abnormal, Clinically Significant0
Week 36 — Normal9
Week 36 — Abnormal, Not Clinically Significant0
Week 36 — Abnormal, Clinically Significant0
Week 48 — Normal6
Week 48 — Abnormal, Not Clinically Significant1
Week 48 — Abnormal, Clinically Significant0
Week 60 — Normal6
Week 60 — Abnormal, Not Clinically Significant1
Week 60 — Abnormal, Clinically Significant0
Week 72 — Normal4
Week 72 — Abnormal, Not Clinically Significant0
Week 72 — Abnormal, Clinically Significant0
Week 84 — Normal3
Week 84 — Abnormal, Not Clinically Significant0
Week 84 — Abnormal, Clinically Significant0
Week 96 — Normal3
Week 96 — Abnormal, Not Clinically Significant0
Week 96 — Abnormal, Clinically Significant0
Week 108 — Normal2
Week 108 — Abnormal, Not Clinically Significant0
Week 108 — Abnormal, Clinically Significant0
Week 120 — Normal1
Week 120 — Abnormal, Not Clinically Significant0
Week 120 — Abnormal, Clinically Significant0
Week 132 — Normal1
Week 132 — Abnormal, Not Clinically Significant0
Week 132 — Abnormal, Clinically Significant0
Survival Follow-Up 1 — Normal5
Survival Follow-Up 1 — Abnormal, Not Clinically Significant0
Survival Follow-Up 1 — Abnormal, Clinically Significant0
Survival Follow-Up 2 — Normal12
Survival Follow-Up 2 — Abnormal, Not Clinically Significant0
Survival Follow-Up 2 — Abnormal, Clinically Significant0
Survival Follow-Up 3 — Normal5
Survival Follow-Up 3 — Abnormal, Not Clinically Significant0
Survival Follow-Up 3 — Abnormal, Clinically Significant0
Survival Follow-Up 4 — Normal1
Survival Follow-Up 4 — Abnormal, Not Clinically Significant1
Survival Follow-Up 4 — Abnormal, Clinically Significant0
Survival Follow-Up 5 — Normal3
Survival Follow-Up 5 — Abnormal, Not Clinically Significant0
Survival Follow-Up 5 — Abnormal, Clinically Significant0
Survival Follow-Up 6 — Normal3
Survival Follow-Up 6 — Abnormal, Not Clinically Significant0
Survival Follow-Up 6 — Abnormal, Clinically Significant0
Survival Follow-Up 7 — Normal2
Survival Follow-Up 7 — Abnormal, Not Clinically Significant0
Survival Follow-Up 7 — Abnormal, Clinically Significant0
Survival Follow-Up 8 — Normal2
Survival Follow-Up 8 — Abnormal, Not Clinically Significant0
Survival Follow-Up 8 — Abnormal, Clinically Significant0
SecondaryNumber of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Hematology Tests Over Time

Clinical laboratory tests for hematology parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.

Time frame:
Baseline, Weeks 18, 36, and 60 (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Hematology Tests Over Time
ParticipantsPertuzumab + Trastuzumab
Overall: Lymphocytes (10^9/L), Low - Grade 33
Overall: Lymphocytes (10^9/L), High - Grade 30
Overall: Lymphocytes (10^9/L), Low - Grade 41
Overall: Lymphocytes (10^9/L), High - Grade 40
Baseline: Lymphocytes (10^9/L), Low - Grade 32
Baseline: Lymphocytes (10^9/L), Low - Grade 40
Week 18: Lymphocytes (10^9/L), Low - Grade 31
Week 18: Lymphocytes (10^9/L), Low - Grade 40
Week 36: Lymphocytes (10^9/L), Low - Grade 31
Week 36: Lymphocytes (10^9/L), Low - Grade 40
Week 60: Lymphocytes (10^9/L), Low - Grade 30
Week 60: Lymphocytes (10^9/L), Low - Grade 41
SecondaryNumber of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Blood Chemistry Tests Over Time

Clinical laboratory tests for blood chemistry parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.

Time frame:
Weeks 6, 12, and 18, and Unscheduled Visits (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Blood Chemistry Tests Over Time
ParticipantsPertuzumab + Trastuzumab
Overall: Glucose (mmol/L), Low - Grade 30
Overall: Glucose (mmol/L), High - Grade 32
Overall: Glucose (mmol/L), Low - Grade 40
Overall: Glucose (mmol/L), High - Grade 40
Week 6: Glucose (mmol/L), High - Grade 31
Week 12: Glucose (mmol/L), High - Grade 31
Week 18: Glucose (mmol/L), High - Grade 31
Overall: Potassium (mmol/L), Low - Grade 30
Overall: Potassium (mmol/L), High - Grade 30
Overall: Potassium (mmol/L), Low - Grade 41
Overall: Potassium (mmol/L), High - Grade 40
Unscheduled Visit: Potassium (mmol/L),Low -Grade 41
SecondaryObserved Trough Serum Concentrations (Cmin) of Pertuzumab at Specified Timepoints

Per protocol eligibility criteria, participants were not required to be pertuzumab naïve; therefore pertuzumab was detectable in some participants pre-dose at Week 1.

Time frame:
Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16
Reported as:
Mean · micrograms per millilitre (ug/mL)
Observed Trough Serum Concentrations (Cmin) of Pertuzumab at Specified Timepoints
micrograms per millilitre (ug/mL)Pertuzumab + Trastuzumab
Week 1 Day 143.12 ± 101.45
Week 4 Day 188.03 ± 29.91
Week 10 Day 194.46 ± 38.47
Week 16 Day 1101.99 ± 41.59
SecondaryMaximum Serum Concentrations (Cmax) of Pertuzumab at Specified Timepoints
Time frame:
Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16
Reported as:
Mean · micrograms per millilitre (ug/mL)
Maximum Serum Concentrations (Cmax) of Pertuzumab at Specified Timepoints
micrograms per millilitre (ug/mL)Pertuzumab + Trastuzumab
Week 1 Day 1275.94 ± 88.80
Week 16 Day 1225.55 ± 56.22
SecondaryObserved Trough Serum Concentrations (Cmin) of Trastuzumab at Specified Timepoints

Per protocol eligibility criteria, participants were not required to be trastuzumab naïve; therefore trastuzumab was detectable in some participants pre-dose at Week 1.

Time frame:
Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16
Reported as:
Mean · micrograms per millilitre (ug/mL)
Observed Trough Serum Concentrations (Cmin) of Trastuzumab at Specified Timepoints
micrograms per millilitre (ug/mL)Pertuzumab + Trastuzumab
Week 1 Day 157.00 ± 52.73
Week 4 Day 1190.82 ± 52.22
Week 10 Day 1294.50 ± 70.33
Week 16 Day 1306.14 ± 90.22
SecondaryMaximum Serum Concentrations (Cmax) of Trastuzumab at Specified Timepoints
Time frame:
Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16
Reported as:
Mean · micrograms per millilitre (ug/mL)
Maximum Serum Concentrations (Cmax) of Trastuzumab at Specified Timepoints
micrograms per millilitre (ug/mL)Pertuzumab + Trastuzumab
Week 1 Day 1181.43 ± 72.49
Week 16 Day 1394.14 ± 94.09
SecondarySymptom Severity Scale Score Over Time, Assessed by Participant Reporting on the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Questionnaire

The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms (Cleeland et al. 2000) that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom severity scale, participants rate the severity of their symptoms in the last 24 hours on 0-10 numeric scales, ranging from 0 = "not present" to 10 = "as bad as you can imagine." The MDASI-BT symptom severity scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 12 of the 22 severity scale items. The score will be considered missing if less than 12 items are completed.

Time frame:
Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64
Reported as:
Mean · Score on a scale
Symptom Severity Scale Score Over Time, Assessed by Participant Reporting on the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Questionnaire
Score on a scalePertuzumab + Trastuzumab
Baseline1.65 ± 1.618
Week 61.97 ± 1.822
Week 122.24 ± 2.141
Week 202.09 ± 2.111
Week 281.94 ± 2.547
Week 402.78 ± 2.856
Week 523.53 ± 3.018
Week 643.12 ± 2.500
SecondarySymptom Interference Scale Score Over Time, Assessed by Participant Reporting on the MDASI-BT Questionnaire

The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom interference scale, participants rate interference with daily activities caused by their symptoms on 0-10 numeric scales ranging from 0 = "did not interfere" to 10 = "interfered completely." The MDASI-BT symptom interference scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 4 of the 6 interference scale items. The score will be considered missing if less than 4 items are completed.

Time frame:
Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64
Reported as:
Mean · Score on a scale
Symptom Interference Scale Score Over Time, Assessed by Participant Reporting on the MDASI-BT Questionnaire
Score on a scalePertuzumab + Trastuzumab
Baseline2.51 ± 2.629
Week 62.23 ± 2.787
Week 122.81 ± 3.391
Week 202.11 ± 2.858
Week 281.76 ± 2.427
Week 403.24 ± 3.548
Week 524.25 ± 3.522
Week 643.93 ± 3.570

Adverse events

Collected over From first dose of study drug until 30 days after last dose of study drug (except for serious AEs related to treatment; up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab + Trastuzumab20/39 (51.3%)7/39 (17.9%)38/39 (97.4%)
Most frequent serious events
Most frequent serious events
EventPertuzumab + Trastuzumab
SeizureNervous system disorders4/39
Gastroenteritis viralInfections and infestations1/39
Parainfluenzae virus infectionInfections and infestations1/39
HeadacheNervous system disorders1/39
HydrocephalusNervous system disorders1/39
HypertensionVascular disorders1/39
Most frequent other events
Showing 10 of 77
Most frequent other events
EventPertuzumab + Trastuzumab
DiarrhoeaGastrointestinal disorders23/39
FatigueGeneral disorders17/39
NauseaGastrointestinal disorders12/39
VomitingGastrointestinal disorders12/39
ConstipationGastrointestinal disorders7/39
DizzinessNervous system disorders7/39
InsomniaPsychiatric disorders7/39
AstheniaGeneral disorders6/39
Upper respiratory tract infectionInfections and infestations6/39
Decreased appetiteMetabolism and nutrition disorders6/39

Baseline characteristics

Intent-to-Treat (ITT) population: all enrolled patients in the study, regardless of whether they were exposed to study treatment.

Age, Continuous
Age, Continuous(Years)Pertuzumab + Trastuzumab
Mean50.0 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab
Female40
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pertuzumab + Trastuzumab
Hispanic or Latino6
Not Hispanic or Latino33
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pertuzumab + Trastuzumab
White36
Asian2
Other Race1
Not Reported1
Women of Childbearing Potential Status
Women of Childbearing Potential Status(Participants)Pertuzumab + Trastuzumab
Childbearing Potential12
Non-Childbearing Potential - Postmenopausal21
Non-Childbearing Potential - Surgically Sterile7
Left Ventricular Ejection Fraction (LVEF) Value at Baseline
Left Ventricular Ejection Fraction (LVEF) Value at Baseline(Percentage Points of LVEF (%))Pertuzumab + Trastuzumab
Median60.00 (50.00 to 75.00)
08

Study locations

16 sites
  • Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • University of Miami Hospital & Clinics
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center and Research Inst.
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611-2987, United States
  • University of Maryland Medical Center; Department of Neurology
    Baltimore, Maryland 21201, United States
  • Associates in Oncology-Hematology, PC
    Bethesda, Maryland 20817, United States
  • Dana Farber Cancer Inst.
    Boston, Massachusetts 02115, United States
  • Allina Health System
    Saint Paul, Minnesota 55102, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Mid Ohio Oncology Hematology;ZangMeister Center (West)
    Columbus, Ohio 43213, United States
  • Temple Cancer Center; Oncology
    Philadelphia, Pennsylvania 19140, United States
  • Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute; University of Utah
    Salt Lake City, Utah 84112, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. J Clin Oncol. 2021 Aug 20;39(24):2667-2675. doi: 10.1200/JCO.20.02822. Epub 2021 May 4. PubMed 33945296 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in May 2019, 40 months.

Results were first posted in Mar 2020, 10 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 40 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2015
First posted
Aug 31, 2015
StartActual
Dec 16, 2015
Primary completionActual
May 1, 2019
CompletionActual
Dec 29, 2020
Results first posted
Mar 27, 2020
Last update
Dec 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02536339
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2015
Start date
Dec 16, 2015
Primary completion
May 1, 2019
Completion
Dec 29, 2020
Results posted
Mar 27, 2020
Last update
Dec 7, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pertuzumab · Trastuzumab

Start the discussion